A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial Ghanizadeh,A, Sahraeizadeh,A and Berk,M 2014, A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial, Child Psychiatry & Human Development, vol. 45, no. 2, pp. 185-192, doi: 10.1007/s10578-013-0390-x. Attached Files Name Description MIMEType Size Downloads Title A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial Author(s) Ghanizadeh,A Sahraeizadeh,A Berk,M orcid.org/0000-0002-5554-6946 Journal name Child Psychiatry & Human Development Volume number 45 Issue number 2 Start page 185 End page 192 Total pages 8 Publisher Springer Place of publication New York, NY Publication date 2014-04 ISSN 1573-3327 Keyword(s) Aripiprazole Autism Clinical trial Randomized Risperidone Treatment Social Sciences Science & Technology Life Sciences & Biomedicine Psychology, Developmental Pediatrics Psychiatry Psychology PSYCHIATRY, SSCI PLACEBO-CONTROLLED TRIAL PEDIATRIC-PATIENTS ABERRANT BEHAVIOR CHILDREN IRRITABILITY ADOLESCENTS Summary Aripiprazole and risperidone are the only FDA approved medications for treating irritability in autistic disorder, however there are no head-to-head data comparing these agents. This is the first prospective randomized clinical trial comparing the safety and efficacy of these two medications in patients with autism spectrum disorders. Fifty nine children and adolescents with autism spectrum disorders were randomized to receive either aripiprazole or risperidone for 2 months. The primary outcome measure was change in Aberrant Behavior Checklist (ABC) scores. Adverse events were assessed. Aripiprazole as well as risperidone lowered ABC scores during 2 months. The rates of adverse effects were not significantly different between the two groups. The safety and efficacy of aripiprazole (mean dose 5.5 mg/day) and risperidone (mean dose 1.12 mg/day) were comparable. The choice between these two medications should be on the basis of clinical equipoise considering the patient's preference and clinical profile. Language eng DOI 10.1007/s10578-013-0390-x Field of Research 110999 Neurosciences not elsewhere classified Socio Economic Objective 920410 Mental Health HERDC Research category C1 Refereed article in a scholarly journal ERA Research output type C Journal article Copyright notice ©2014, Springer Persistent URL http://hdl.handle.net/10536/DRO/DU:30067200 Document type: Journal Article Collections: Faculty of Health School of Medicine Related Links Link Description Connect to published version Go to link with your DU access privileges   Author URL Go to link with your DU access privileges     Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved. Versions Version Filter Type Mon, 03 Nov 2014, 14:38:23 EST Mon, 08 Dec 2014, 10:55:45 EST Mon, 08 Dec 2014, 11:11:29 EST Mon, 08 Dec 2014, 11:19:01 EST Wed, 10 Dec 2014, 09:13:39 EST Wed, 10 Dec 2014, 09:14:33 EST Wed, 14 Oct 2015, 13:53:59 EST Filtered Full Citation counts:   Cited 52 times in TR Web of Science Cited 51 times in Scopus Search Google Scholar Access Statistics: 637 Abstract Views, 3 File Downloads  -  Detailed Statistics Created: Mon, 08 Dec 2014, 10:55:45 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.